Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | OXTR | P30559 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9853243 | 0.82 | GAA (0.69) | GAANPSR1MEN1MAPTKMT2A | |
| SCHEMBL9266525 | 0.81 | GAA (0.67) | GAANPSR1MEN1MAPTKMT2A | |
| SCHEMBL8557450 | 0.81 | GAA (0.67) | GAANPSR1MEN1MAPTKMT2A | |
| SCHEMBL6970933 | 0.81 | NPSR1 (0.67) | GAANPSR1MEN1MAPTKMT2A | |
| SCHEMBL8560344 | 0.81 | GAA (0.67) | GAANPSR1MEN1MAPTKMT2A | |
| SCHEMBL8563763 | 0.81 | NPSR1 (0.67) | GAANPSR1MEN1MAPTKMT2A | |
| SCHEMBL9266460 | 0.81 | GAA (0.67) | GAANPSR1MEN1MAPTKMT2A | |
| SCHEMBL8556344 | 0.81 | NPSR1 (0.67) | GAANPSR1MEN1MAPTKMT2A | |
| SCHEMBL8556755 | 0.81 | GAA (0.67) | GAANPSR1MEN1MAPTKMT2A | |
| SCHEMBL7885518 | 0.81 | GAA (0.67) | GAANPSR1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065809-A1 | TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES | 712 NORTH INC. | 2023-03-02 | — | — | US | claimed |
| US-12466819-B2 | Tricyclic compounds with OMA1/OPA1 modulatory properties | 712 NORTH INC. (US) | 2025-11-11 | — | — | US | disclosed |
| CN-119285628-A | Compounds for the treatment and prophylaxis of respiratory syncytial virus infection diseases | 石药集团中奇制药技术（石家庄）有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20230065809-A1 | TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES | 712 NORTH INC. | 2023-03-02 | — | — | US | disclosed |
| US-11046889-B2 | Polymerizable compound and optically anisotropic body | DIC CORPORATION (JP) | 2021-06-29 | — | — | US | disclosed |
| US-10919870-B2 | Polymerizable compound and optically anisotropic body | DIC CORPORATION (JP) | 2021-02-16 | — | — | US | disclosed |
| US-10649124-B2 | Composition including compound having mesogenic group, polymer and optically anisotropic body obtained by polymerizing polymerizable composition, and phase difference film | DIC CORPORATION (JP) | 2020-05-12 | — | — | US | disclosed |
| US-10633353-B2 | Polymerizable compound, composition, polymer, optically anisotropic body, liquid crystal display element, and organic EL display | DIC CORPORATION (JP) | 2020-04-28 | — | — | US | disclosed |
| EP-3256468-B1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-04-08 | — | — | EP | disclosed |
| US-10428032-B2 | Polymerizable compound and optically anisotropic body | DIC CORPORATION (JP) | 2019-10-01 | — | — | US | disclosed |
| US-5182272-A | 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain | G. D. SEARLE & CO. (US) | 1993-01-26 | — | — | US | disclosed |
| US-5180720-A | Prostaglandin E2 antagonists | G. D. SEARLE & CO. (US) | 1993-01-19 | — | — | US | disclosed |
| WO-1992019605-A1 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G. D. SEARLE & CO. (US) | 1992-11-12 | — | — | WO | disclosed |
| WO-1992019617-A2 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0512399-A1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. Searle & Co. (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0512400-A1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. Searle & Co. (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0480641-A1 | Tricyclic heterocycles | ZENECA LIMITED (GB) | 1992-04-15 | — | — | EP | disclosed |
| US-4888335-A | HYPOTENSIVE AGENTS | MCNEILAB, INC. (US) | 1989-12-19 | — | — | US | disclosed |
| US-4170593-A | ANTIINFLAMMATORY, ANTIDIARRHEA | G. D. SEARLE & CO. (US) | 1979-10-09 | — | — | US | disclosed |
| US-4045442-A | ANTIINFLAMMATORY, ANTIDIARRHEA | G. D. SEARLE & CO. (US) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919870-B2 | Polymerizable compound and optically anisotropic body | ZYX, ZW10, DPY30 | GAA 2711/4885NPSR1 3884/4885MEN1 2026/4885 |
| US-10428032-B2 | Polymerizable compound and optically anisotropic body | CCNY, F12, CCNI | GAA 2568/4885NPSR1 3396/4885MEN1 857/4885 |
| US-10633353-B2 | Polymerizable compound, composition, polymer, optically anisotropic body, liquid crystal display element, and organic EL display | RPL19, RPL24, RPL29 | GAA 2314/4885NPSR1 2522/4885MEN1 3962/4885 |
| US-11046889-B2 | Polymerizable compound and optically anisotropic body | OCIAD1, RCC1, OCIAD2 | GAA 3881/4885NPSR1 2540/4885MEN1 2528/4885 |
| US-20230065809-A1 | TRICYCLIC COMPOUNDS WITH OMA1/OPA1 MODULATORY PROPERTIES | OPA1, OLA1, ACOX1 | GAA 402/4885NPSR1 4430/4885MEN1 1885/4885 |
| US-12466819-B2 | Tricyclic compounds with OMA1/OPA1 modulatory properties | OPA1, OLA1, ACOX1 | GAA 402/4885NPSR1 4430/4885MEN1 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.